clinical trial · NCT07325136
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb·phase2·recruiting·n = 240
Relapsed/Refractory Small Cell Lung CancerBMS-986525Pumitamig
brief summary
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
started
Feb 3, 2026
primary completion
Apr 23, 2029
completion
Apr 24, 2029
last updated
Aug 18, 2026
official title
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol